Articles by Mário F. Neto in JoVE
Investigando as proteínas príon-like espalhando e de toxicidade de usar o Metazoan Organismo Modelo Carmen I. Nussbaum-Krammer1, Mário F. Neto1, Renée M. Brielmann1, Jesper S. Pedersen1, Richard I. Morimoto1 1Department of Molecular Biosciences, Rice Institute for Biomedical Research, Northwestern University
Isolamento de filtração de Ácidos Nucleicos: Um Método de extracção de DNA simples e rápido Sally M. McFall1, Mário F. Neto1, Jennifer L. Reed1, Robin L. Wagner2 1Center for Innovation in Global Health Technologies (CIGHT), Department of Biomedical Engineering, Northwestern University, 2Pritzker School of Medicine, The University of Chicago Descrevemos aqui um método de extração de DNA simples e rápido em papel de DNA pró-viral do HIV de sangue total detectado por PCR quantitativa. Este protocolo pode ser estendida para utilização na detecção de outros marcadores genéticos, ou utilizando métodos de amplificação alternativos.
Other articles by Mário F. Neto on PubMed
Serotonergic Signalling Suppresses Ataxin 3 Aggregation and Neurotoxicity in Animal Models of Machado-Joseph Disease Brain : a Journal of Neurology. Nov, 2015 | Pubmed ID: 26373603 Polyglutamine diseases are a class of dominantly inherited neurodegenerative disorders for which there is no effective treatment. Here we provide evidence that activation of serotonergic signalling is beneficial in animal models of Machado-Joseph disease. We identified citalopram, a selective serotonin reuptake inhibitor, in a small molecule screen of FDA-approved drugs that rescued neuronal dysfunction and reduced aggregation using a Caenorhabditis elegans model of mutant ataxin 3-induced neurotoxicity. MOD-5, the C. elegans orthologue of the serotonin transporter and cellular target of citalopram, and the serotonin receptors SER-1 and SER-4 were strong genetic modifiers of ataxin 3 neurotoxicity and necessary for therapeutic efficacy. Moreover, chronic treatment of CMVMJD135 mice with citalopram significantly reduced ataxin 3 neuronal inclusions and astrogliosis, rescued diminished body weight and strikingly ameliorated motor symptoms. These results suggest that small molecule modulation of serotonergic signalling represents a promising therapeutic target for Machado-Joseph disease.